Community Pharmacy England News

- 4TH JULY 2025
- 0 COMMENTS
Medicine Supply Notification: Salbutamol 100micrograms/dose breath actuated inhalers CFC free
The Department of Health and Social Care (DHSC) has issued a medicine supply notification for the following product: Salbutamol 100micrograms/dose breath actuated inhalers CFC free MSN/2025/041 Tier 2 – medium impact Date of issue: 04/07/2025 Salbutamol (Salamol Easi-Breathe®) 100micrograms/dose breath actuated inhaler CFC free is out of stock until mid-September 2025; following resupply, stock will
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 4TH JULY 2025
- 0 COMMENTS
South Western and South Eastern Pharmacy Owners: Book on your local Future of Pharmacy workshop
With the conclusion of the NHS 10-Year Health Plan imminent, this is a critical time for community pharmacy and it is important that we focus on the future, including looking at negotiating priorities to further leverage community pharmacy’s position. Pharmacy owners across the South West and South East are invited to ‘Future of Pharmacy’ workshop
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 3RD JULY 2025
- 0 COMMENTS
National Patient Safety Alert: Shortage Of Bumetanide 1mg Tablets
National Patient Safety Alert: Shortage Of Bumetanide 1mg Tablets National Patient Safety Alert Reference Number: NatPSA/2025/003/DHSC Date issued: 03 July 2025 Explanation of identified safety issue Bumetanide 1mg tablets are out of stock until mid-August 2025. The supply disruption is caused by a combination of manufacturing issues and a resulting increase in demand to other
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 3RD JULY 2025
- 0 COMMENTS
10-Year Plan: Community pharmacies to play vital role in LTC support and vaccine delivery
A plan to reform the health service – which includes a bigger role for community pharmacies – has been published by the Government today. The highly anticipated 10-Year Health Plan sets out the Government’s priorities for healthcare in this Parliament and the next. For community pharmacy, the plan outlines an increasing role in the management
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 3RD JULY 2025
- 0 COMMENTS
MHRA Class 4 Medicines Defect Notification: Simvastatin 10mg Tablet (Crescent Pharma Ltd)
MHRA Class 4 Medicines Defect Notification: Simvastatin 10mg Tablet (Crescent Pharma Ltd) Date issued: 03 July 2025 Drug Alert Number: EL(25)A/33 Crescent Pharma Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of a batch of simvastatin 10 mg Tablets distributed by Alliance Healthcare UK. DMRC reference
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 2ND JULY 2025
- 0 COMMENTS
10-Year Health Plan to be announced
Tomorrow (Thursday 3rd July 2025), the Government will announce how millions more patients will be treated closer to home with the roll out of Neighbourhood Health Services across the country as part of its 10-Year Health Plan. PM launches new era for NHS with easier care in neighbourhoods | GOV.UK Further information to follow. Below
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 2ND JULY 2025
- 0 COMMENTS
Rolled over price concessions for July 2025
The following price concessions granted in June 2025 have rolled over to July 2025: Drug Pack size June 2025 price concession Co-amoxiclav 250mg/62mg/5ml oral suspension 100 £5.06 Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free 100 £4.79 Fenofibrate micronised 160mg tablets 28 £3.60 Nizatidine 150mg capsules 30 £21.69 Sulfasalazine 500mg tablets 112 £6.61 Please note any rolled
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 2ND JULY 2025
- 0 COMMENTS
EPS rolls out across Wales
NHS England has announced that the rollout of the Electronic Prescription Service (EPS) is well underway across primary care in Wales. As of June 2025: All seven pharmacy system suppliers operating in Wales now support EPS. The majority of pharmacies in Wales are now able to receive electronic prescriptions. EPS utilisation is estimated to be
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 1ST JULY 2025
- 0 COMMENTS
June 2025 Price Concessions Final Update
The Department of Health and Social Care (DHSC) has today (01/07/2025) confirmed the following final list of price concessions for June 2025. Drug Pack size Price concession Ascorbic acid 100mg tablets 28 £26.89 Co-amoxiclav 250mg/62mg/5ml oral suspension 100 £5.06 Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free 100 £4.79 Fenofibrate micronised 160mg tablets 28 £3.60 Mercaptopurine 50mg tablets
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 1ST JULY 2025
- 0 COMMENTS
Rollout of prescription status info in the NHS App continues
The National Patient Prescription Tracking Service (NPPTS) enables patients to access and track their prescriptions online through the NHS App or their NHS account (by logging in on the NHS website). NPPTS is a feature of the Electronic Prescription Service (EPS) that utilises a combination of Spine and Pharmacy IT supplier systems’ information to provide
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News

Medicine Supply Notification: Salbutamol 100micrograms/dose breath actuated inhalers CFC free

South Western and South Eastern Pharmacy Owners: Book on your local Future of Pharmacy workshop

National Patient Safety Alert: Shortage Of Bumetanide 1mg Tablets

10-Year Plan: Community pharmacies to play vital role in LTC support and vaccine delivery

MHRA Class 4 Medicines Defect Notification: Simvastatin 10mg Tablet (Crescent Pharma Ltd)

10-Year Health Plan to be announced

Rolled over price concessions for July 2025

EPS rolls out across Wales

June 2025 Price Concessions Final Update

Rollout of prescription status info in the NHS App continues

Get in Touch

Working together with key healthcare stakeholders, local councils and other healthcare organisations as necessary to ensure that the provision of pharmaceutical services continues to be an integral part of Health and Social Care